Wall Street analyst estimates for Editas Medicine, Inc. (EDIT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.21 | ||
| 2026-08-05 | $-0.15 | $-0.27 | +44.5% |
| 2026-05-05 | $-0.26 | $-0.30 | +13.3% |
| 2026-03-09 | $-0.06 | $-0.27 | +77.8% |
| 2025-11-10 | $-0.28 | $-0.38 | +26.3% |
| 2025-08-12 | $-0.63 | $-0.41 | -53.7% |
| 2025-05-12 | $-0.92 | $-0.56 | -63.1% |
| 2025-03-05 | $-0.55 | $-0.39 | -41.0% |
Valuation Ratios
| Price / Book | 2.88 |
| EV / EBITDA | -4.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Cost of Revenue | $57.0M | $83.2M | $90.7M | $96.9M | $158.0M | $5.1M | $6.3M | $6.1M | $199.2M | 0 |
| Gross Profit | -$50.9M | -$69.4M | -$58.7M | -$76.4M | -$67.3M | $20.5M | $13.4M | $72.1M | -$166.9M | $40.5M |
| Research & Development | $57.0M | $83.2M | $90.7M | $96.9M | $158.0M | $142.5M | $175.0M | $177.7M | $199.2M | $90.0M |
| Selling, General & Admin | $46.3M | $50.5M | $55.0M | $64.6M | $67.6M | $76.2M | $70.7M | $69.7M | $72.0M | $49.9M |
| Operating Expenses | $103.2M | $133.7M | $145.7M | $64.6M | $67.6M | $213.6M | $239.3M | $241.2M | $84.2M | $139.9M |
| Operating Income | -$97.2M | -$119.9M | -$113.7M | -$140.9M | -$134.8M | -$193.1M | -$225.9M | -$169.2M | -$251.2M | -$99.3M |
| EBITDA | -$96.1M | -$116.7M | -$110.5M | -$138.1M | -$130.9M | -$187.4M | -$214.1M | -$147.2M | -$233.1M | -$148.6M |
| Interest Expense | 0 | $978000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $6.2M |
| Pre-tax Income | -$97.2M | -$120.3M | -$110.0M | -$133.7M | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| Income Tax | 0 | -$1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$97.2M | -$120.3M | -$110.0M | -$133.7M | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| EPS | $-3.02 | $-2.98 | $-2.33 | $-2.47 | $-1.98 | $-2.85 | $-3.21 | $-2.02 | $-2.88 | $-1.80 |
| EPS (Diluted) | $-3.02 | $-2.98 | $-2.33 | $-2.47 | $-1.98 | $-2.85 | $-3.21 | $-2.02 | $-2.88 | $-1.80 |
| Shares Outstanding (Diluted) | $32.2M | $40.3M | $47.1M | $50.0M | $58.6M | $67.6M | $68.7M | $76.0M | $82.3M | $88.7M |
Price
| Price | $2.71 |
| Market Cap | $416M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLO · AVIR · CABA · CAPR · IMMP · KYTX · LYEL
Explore sector: Healthcare · Biotechnology
More sections of EDIT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks